Skip to Content

Funda Meric-Bernstam, MD

Present Title & Affiliation

Primary Appointment

Department Chair, Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX
Medical Director, Khalifa Institute for Personalized Cancer Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX
Nellie B. Connally Chair in Breast Cancer Research, Department of Investigational Cancer Therapeutics, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX
Professor, Department of Surgical Oncology, Division of Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX

Dual/Joint/Adjunct Appointment

Regular Member, University of Texas Houston Graduate School of Biomedical Sciences, Houston, TX

Bio Statement

Funda Meric-Bernstam is a  Professor of Surgical Oncology at the University of Texas M. D. Anderson Cancer Center in Houston, Texas. She is also a member of the University of Texas at Houston Graduate School of Biomedical Sciences Faculty. Dr. Meric-Bernstam graduated Cum Laude from Yale University School of Medicine in 1991 and completed her residency in general surgery at the University of Michigan Medical Center in 1998. In her third year of residency, she joined the National Institutes of Health as a postdoctoral fellow. During her time at the NIH, she received the NIH Intramural National Research Service Award as well as the NIH Fellows Award for Research Excellence.  After her general surgery residency she did a surgical oncology fellowship at M.D. Anderson Cancer. She joined M. D. Anderson's faculty in 2001 as a surgeon and researcher. In 2005, Dr. Meric-Bernstam received the Outstanding Teaching Award for Research from the Department of Surgical Oncology at the University of Texas M.D. Anderson Cancer Center. Dr. Meric-Bernstam is an active member of the American Medical Association, American Association of Cancer Research, American College of Surgeons, American Society of Clinical Oncology, Society of Surgical Oncology, Society of University Surgeons and the Houston Medical Society. Dr. Meric-Bernstam has authored over 140 peer-reviewed articles in journals such as Journal of Clinical Oncology, Cancer Research, Clinical Cancer Research, Molecular Cancer Therapeutics and Annals of Surgical Oncology. She has also written chapters for more than 15 books.

Research Interests

Dr. Meric-Bernstam has an active basic, translational and clinical  research program focused on breast cancer biology and novel breast cancer therapies.

Education & Training

Degree-Granting Education

1991 Yale University School of Medicine, New Haven, CT, MD, Cum Laude, Medicine

Board Certifications

1/1999 American Board of Surgery, Recertification Date: 11/2007

Selected Publications

Peer-Reviewed Original Research Articles

1. Blanco E, Sangai T, Hsiao A, Ferrati S, Bai L, Liu X, Meric-Bernstam F, Ferrari M. Multistage delivery of chemotherapeutic nanoparticles for breast cancer treatment. Cancer Lett 334(2):245-52, 7/1/2013. e-Pub 7/31/2012. PMID: 22858582.
2. Gonzalez-Angulo AM, Chen H, Karuturi MS, Chavez-MacGregor M, Tsavachidis S, Meric-Bernstam F, Do KA, Hortobagyi GN, Thompson PA, Mills GB, Bondy ML, Blumenschein GR. Frequency of mesenchymal-epithelial transition factor gene (MET) and the catalytic subunit of phosphoinositide-3-kinase (PIK3CA) copy number elevation and correlation with outcome in patients with early stage breast cancer. Cancer 119(1):7-15, 1/1/2013. e-Pub 6/26/2012. PMCID: PMC3461089.
3. Kong AL, Tereffe W, Hunt KK, Yi M, Kang T, Weatherspoon K, Mittendorf EA, Bedrosian I, Hwang RF, Babiera GV, Buchholz TA, Meric-Bernstam F. Impact of internal mammary lymph node drainage identified by preoperative lymphoscintigraphy on outcomes in patients with stage I to III breast cancer. Cancer 118(24):6287-96, 12/15/2012. e-Pub 5/30/2012. PMID: 22648744.
4. Lynch SP, Lei X, Chavez-Macgregor M, Hsu L, Meric-Bernstam F, Buchholz TA, Zhang A, Hortobagyi GN, Valero V, Gonzalez-Angulo AM. Multifocality and multicentricity in breast cancer and survival outcomes. Ann Oncol 23(12):3063-9, 12/2012. e-Pub 7/9/2012. PMCID: PMC3501230.
5. Alvarado R, Lari SA, Roses RE, Smith BD, Yang W, Mittendorf EA, Arun BK, Lucci A, Babiera GV, Wagner JL, Caudle AS, Meric-Bernstam F, Hwang RF, Bedrosian I, Hunt KK, Kuerer HM. Biology, Treatment, and Outcome in Very Young and Older Women with DCIS. Ann Surg Oncol 19(12):3777-84, 11/2012. e-Pub 5/24/2012. PMID: 22622473.
6. Kim MM, Dawood S, Allen P, Sahin AA, Woodward WA, Smith BD, Strom EA, Hunt KK, Meric-Bernstam F, Gonzalez-Angulo AM, Buchholz TA. Hormone receptor status influences the locoregional benefit of trastuzumab in patients with nonmetastatic breast cancer. Cancer 118(20):4936-43, 10/15/2012. e-Pub 4/17/2012. PMID: 22511276.
7. Caudle AS, Hunt KK, Tucker SL, Hoffman K, Gainer SM, Lucci A, Kuerer HM, Meric-Bernstam F, Shah R, Babiera GV, Sahin AA, Mittendorf EA. American College of Surgeons Oncology Group (ACOSOG) Z0011: Impact on Surgeon Practice Patterns. Ann Surg Oncol 19(10):3144-51, 10/2012. e-Pub 7/31/2012. PMID: 22847123.
8. Su X, Zhang L, Zhang J, Meric-Bernstam F, Weinstein JN. PurityEst: estimating purity of human tumor samples using next-generation sequencing data. Bioinformatics 28(17):2265-6, 9/1/2012. e-Pub 6/28/2012. PMCID: PMC3426843.
9. Meric-Bernstam F, Mills GB. Overcoming implementation challenges of personalized cancer therapy. Nat Rev Clin Oncol 9(9):542-8, 9/2012. e-Pub 7/31/2012. PMID: 22850751.
10. Kuerer HM, Lari SA, Arun BK, Hu CY, Brewster A, Mittendorf EA, Albarracin CT, Babiera GV, Caudle AS, Wagner JL, Litton JK, Bedrosian I, Meric-Bernstam F, Lucci A, Hunt KK. Biologic features and prognosis of ductal carcinoma in situ are not adversely impacted by initial large body mass. Breast Cancer Res Treat 133(3):1131-41, 6/2012. e-Pub 3/4/2012. PMID: 22392043.
11. Bayraktar S, Gonzalez-Angulo AM, Lei X, Buzdar AU, Valero V, Melhem-Bertrandt A, Kuerer HM, Hortobagyi GN, Sahin AA, Meric-Bernstam F. Efficacy of neoadjuvant therapy with trastuzumab concurrent with anthracycline- and nonanthracycline-based regimens for HER2-positive breast cancer. Cancer 118(9):2385-93, 5/1/2012. e-Pub 9/27/2011. PMCID: PMC3274632.
12. Dominici LS, Mittendorf EA, Wang X, Liu J, Kuerer HM, Hunt KK, Brewster A, Babiera GV, Buchholz TA, Meric-Bernstam F, Bedrosian I. Implications of constructed biologic subtype and its relationship to locoregional recurrence following mastectomy. Breast Cancer Res 14(3). e-Pub 5/23/2012. PMID: 22621306.
13. Caudle AS, Yu TK, Tucker SL, Bedrosian I, Litton JK, Gonzalez-Angulo AM, Hoffman K, Meric-Bernstam F, Hunt KK, Buchholz TA, Mittendorf EA. Local-regional control according to surrogate markers of breast cancer subtypes and response to neoadjuvant chemotherapy in breast cancer patients undergoing breast conserving therapy. Breast Cancer Res 14(3). e-Pub 5/23/2012. PMID: 22621334.
14. Abbott DE, Brouquet A, Mittendorf EA, Andreou A, Meric-Bernstam F, Valero V, Green MC, Kuerer HM, Curley SA, Abdalla EK, Hunt KK, Vauthey JN. Resection of liver metastases from breast cancer: estrogen receptor status and response to chemotherapy before metastasectomy define outcome. Surgery 151(5):710-6, 5/2012. e-Pub 1/29/2012. PMID: 22285778.
15. Raghav KP, Wang W, Liu S, Chavez-MacGregor M, Meng X, Hortobagyi GN, Mills GB, Meric-Bernstam F, Blumenschein GR, Gonzalez-Angulo AM. cMET and phospho-cMET protein levels in breast cancers and survival outcomes. Clin Cancer Res 18(8):2269-77, 4/15/2012. e-Pub 2/28/2012. PMID: 22374333.
16. Wagner JL, Fearmonti R, Hunt KK, Hwang RF, Meric-Bernstam F, Kuerer HM, Bedrosian I, Crosby MA, Baumann DP, Ross MI, Feig BW, Krishnamurthy S, Hernandez M, Babiera GV. Prospective evaluation of the nipple-areola complex sparing mastectomy for risk reduction and for early-stage breast cancer. Ann Surg Oncol 19(4):1137-44, 4/2012. e-Pub 10/7/2011. PMID: 21979111.
17. Bayraktar S, Hernadez-Aya LF, Lei X, Meric-Bernstam F, Litton JK, Hsu L, Hortobagyi GN, Gonzalez-Angulo AM. Effect of metformin on survival outcomes in diabetic patients with triple receptor-negative breast cancer. Cancer 118(5):1202-11, 3/1/2012. e-Pub 7/28/2011. PMCID: PMC3207034.
18. Raghav KP, Hernandez-Aya LF, Lei X, Chavez-Macgregor M, Meric-Bernstam F, Buchholz TA, Sahin A, Do KA, Hortobagyi GN, Gonzalez-Angulo AM. Impact of low estrogen/progesterone receptor expression on survival outcomes in breast cancers previously classified as triple negative breast cancers. Cancer 118(6):1498-506, 3/15/2012. e-Pub 8/11/2011. PMCID: PMC3217101.
19. Meric-Bernstam F, Akcakanat A, Chen H, Do KA, Sangai T, Adkins F, Gonzalez-Angulo AM, Rashid A, Crosby K, Dong M, Phan AT, Wolff RA, Gupta S, Mills GB, Yao J. PIK3CA/PTEN mutations and Akt activation as markers of sensitivity to allosteric mTOR inhibitors. Clin Cancer Res 18(6):1777-89, 3/15/2012. PMCID: PMC3307149.
20. Bayraktar S, Elsayegh N, Gutierrez Barrera AM, Lin H, Kuerer H, Tasbas T, Muse KI, Ready K, Litton J, Meric-Bernstam F, Hortobagyi GN, Albarracin CT, Arun B. Predictive factors for BRCA1/BRCA2 mutations in women with ductal carcinoma in situ. Cancer 118(6):1515-22, 3/15/2012. e-Pub 8/25/2011. PMID: 22009639.
21. Akay CL, Meric-Bernstam F, Hunt KK, Grubbs EG, Bedrosian I, Tucker SL, Kuerer HM, Hoffman KE, Babiera GV, Strom EA, Buchholz TA, Mittendorf EA. Evaluation of the MD Anderson Prognostic Index for local-regional recurrence after breast conserving therapy in patients receiving neoadjuvant chemotherapy. Ann Surg Oncol 19(3):901-7, 3/2012. e-Pub 8/23/2011. PMID: 21861223.
22. Yi M, Meric-Bernstam F, Kuerer HM, Mittendorf EA, Bedrosian I, Lucci A, Hwang RF, Crow JR, Luo S, Hunt KK. Evaluation of a breast cancer nomogram for predicting risk of ipsilateral breast tumor recurrences in patients with ductal carcinoma in situ after local excision. J Clin Oncol 30(6):600-7, 2/20/2012. e-Pub 1/17/2012. PMCID: PMC3295558.
23. Gonzalez-Angulo AM, Iwamoto T, Liu S, Chen H, Do KA, Hortobagyi GN, Mills GB, Meric-Bernstam F, Symmans WF, Pusztai L. Gene expression, molecular class changes, and pathway analysis after neoadjuvant systemic therapy for breast cancer. Clin Cancer Res 18(4):1109-19, 2/15/2012. e-Pub 1/10/2012. PMCID: PMC3288822.
24. Litton JK, Ready K, Chen H, Gutierrez-Barrera A, Etzel CJ, Meric-Bernstam F, Gonzalez-Angulo AM, Le-Petross H, Lu K, Hortobagyi GN, Arun BK. Earlier age of onset of BRCA mutation-related cancers in subsequent generations. Cancer 118(2):321-5, 1/15/2012. e-Pub 9/12/2011. PMID: 21913181.
25. Mittendorf EA, Hunt KK, Boughey JC, Bassett R, Degnim AC, Harrell R, Yi M, Meric-Bernstam F, Ross MI, Babiera GV, Kuerer HM, Hwang RF. Incorporation of sentinel lymph node metastasis size into a nomogram predicting nonsentinel lymph node involvement in breast cancer patients with a positive sentinel lymph node. Ann Surg 255(1):109-15, 1/2012. PMID: 22167004.
26. Hatzis C, Sun H, Yao H, Hubbard RE, Meric-Bernstam F, Babiera GV, Wu Y, Pusztai L, Symmans WF. Effects of tissue handling on RNA integrity and microarray measurements from resected breast cancers. J Natl Cancer Inst 103(24):1871-83, 12/21/2011. e-Pub 10/27/2011. PMCID: PMC3243675.
27. Blanco E, Hsiao A, Ruiz-Esparza GU, Landry MG, Meric-Bernstam F, Ferrari M. Molecular-targeted nanotherapies in cancer: enabling treatment specificity. Mol Oncol 5(6):492-503, 12/2011. e-Pub 10/25/2011. PMID: 22071376.
28. Bayraktar S, Gutierrez-Barrera AM, Liu D, Tasbas T, Akar U, Litton JK, Lin E, Albarracin CT, Meric-Bernstam F, Gonzalez-Angulo AM, Hortobagyi GN, Arun BK. Outcome of triple-negative breast cancer in patients with or without deleterious BRCA mutations. Breast Cancer Res Treat 130(1):145-53, 11/2011. e-Pub 8/10/2011. PMID: 21830012.
29. Hong DS, Kurzrock R, Oh Y, Wheler J, Naing A, Brail L, Callies S, André V, Kadam SK, Nasir A, Holzer TR, Meric-Bernstam F, Fishman M, Simon G. A phase 1 dose escalation, pharmacokinetic, and pharmacodynamic evaluation of eIF-4E antisense oligonucleotide LY2275796 in patients with advanced cancer. Clin Cancer Res 17(20):6582-91, 10/15/2011. e-Pub 8/10/2011. PMID: 21831956.
30. Arun B, Bayraktar S, Liu DD, Gutierrez Barrera AM, Atchley D, Pusztai L, Litton JK, Valero V, Meric-Bernstam F, Hortobagyi GN, Albarracin C. Response to neoadjuvant systemic therapy for breast cancer in BRCA mutation carriers and noncarriers: a single-institution experience. J Clin Oncol 29(28):3739-46, 10/1/2011. e-Pub 9/6/2011. PMID: 21900106.
31. Theriault RL, Litton JK, Mittendorf EA, Chen H, Meric-Bernstam F, Chavez-Macgregor M, Morrow PK, Woodward WA, Sahin A, Hortobagyi GN, Gonzalez-Angulo AM. Age and survival estimates in patients who have node-negative T1ab breast cancer by breast cancer subtype. Clin Breast Cancer 11(5):325-31, 10/2011. e-Pub 7/20/2011. PMID: 21764391.
32. Adkins FC, Gonzalez-Angulo AM, Lei X, Hernandez-Aya LF, Mittendorf EA, Litton JK, Wagner J, Hunt KK, Woodward WA, Meric-Bernstam F. Triple-negative breast cancer is not a contraindication for breast conservation. Ann Surg Oncol 18(11):3164-73, 10/2011. e-Pub 9/2011. PMID: 21947595.
33. Lang JY, Hsu JL, Meric-Bernstam F, Chang CJ, Wang Q, Bao Y, Yamaguchi H, Xie X, Woodward WA, Yu D, Hortobagyi GN, Hung MC. BikDD eliminates breast cancer initiating cells and synergizes with lapatinib for breast cancer treatment. Cancer Cell 20(3):341-56, 9/2011. PMCID: PMC3172580.
34. Caudle AS, Hunt KK, Kuerer HM, Meric-Bernstam F, Lucci A, Bedrosian I, Babiera GV, Hwang RF, Ross MI, Feig BW, Hoffman K, Litton JK, Sahin AA, Yang W, Hortobagyi GN, Buchholz TA, Mittendorf EA. Multidisciplinary considerations in the implementation of the findings from the American College of Surgeons Oncology Group (ACOSOG) Z0011 study: a practice-changing trial. Ann Surg Oncol 18(9):2407-12, 9/2011. PMID: 21327455.
35. Melhem-Bertrandt A, Chavez-Macgregor M, Lei X, Brown EN, Lee RT, Meric-Bernstam F, Sood AK, Conzen SD, Hortobagyi GN, Gonzalez-Angulo AM. Beta-blocker use is associated with improved relapse-free survival in patients with triple-negative breast cancer. J Clin Oncol 29(19):2645-52, 7/1/2011. e-Pub 5/31/2011. PMCID: PMC3139371.
36. Hernandez-Aya LF, Chavez-Macgregor M, Lei X, Meric-Bernstam F, Buchholz TA, Hsu L, Sahin AA, Do KA, Valero V, Hortobagyi GN, Gonzalez-Angulo AM. Nodal status and clinical outcomes in a large cohort of patients with triple-negative breast cancer. J Clin Oncol 29(19):2628-34, 7/1/2011. e-Pub 5/23/2011. PMCID: PMC3139370.
37. Wagner JL, Warneke CL, Mittendorf EA, Bedrosian I, Babiera GV, Kuerer HM, Hunt KK, Yang W, Sahin AA, Meric-Bernstam F. Delays in primary surgical treatment are not associated with significant tumor size progression in breast cancer patients. Ann Surg 254(1):119-24, 7/2011. PMID: 21494124.
38. Blanco E, Hsiao A, Mann AP, Landry MG, Meric-Bernstam F, Ferrari M. Nanomedicine in cancer therapy: innovative trends and prospects. Cancer Sci 102(7):1247-52, 7/2011. e-Pub 5/3/2011. PMID: 21447010.
39. Feldman S, Krishnamurthy S, Gillanders W, Gittleman M, Beitsch PD, Young PR, Streck CJ, Whitworth PW, Levine EA, Boolbol S, Han LK, Hermann R, Hoon DS, Giuliano AE, Meric-Bernstam F, US One Step Nucleic Acid Amplification Clinical Study Group. A novel automated assay for the rapid identification of metastatic breast carcinoma in sentinel lymph nodes. Cancer 117(12):2599-607, 6/15/2011. e-Pub 1/11/2011. PMID: 21226034.
40. Langsner RJ, Middleton LP, Sun J, Meric-Bernstam F, Hunt KK, Drezek RA, Yu TK. Wide-field imaging of fluorescent deoxy-glucose in ex vivo malignant and normal breast tissue. Biomed Opt Express 2(6):1514-23, 6/1/2011. e-Pub 5/11/2011. PMCID: PMC3114220.
41. Gonzalez-Angulo AM, Ferrer-Lozano J, Stemke-Hale K, Sahin A, Liu S, Barrera JA, Burgues O, Lluch AM, Chen H, Hortobagyi GN, Mills GB, Meric-Bernstam F. PI3K pathway mutations and PTEN levels in primary and metastatic breast cancer. Mol Cancer Ther 10(6):1093-101, 6/2011. e-Pub 4/2011. PMCID: PMC3112276.
42. Yi M, Kronowitz SJ, Meric-Bernstam F, Feig BW, Symmans WF, Lucci A, Ross MI, Babiera GV, Kuerer HM, Hunt KK. Local, regional, and systemic recurrence rates in patients undergoing skin-sparing mastectomy compared with conventional mastectomy. Cancer 117(5):916-24, 3/1/2011. e-Pub 10/13/2010. PMID: 20945319.
43. Ready K, Gutierrez-Barrera AM, Amos C, Meric-Bernstam F, Lu K, Hortobagyi G, Arun B. Cancer risk management decisions of women with BRCA1 or BRCA2 variants of uncertain significance. Breast J 17(2):210-2, Mar-Apr, 3/2011. e-Pub 2/7/2011. PMID: 21294809.
44. Yi M, Buchholz TA, Meric-Bernstam F, Bedrosian I, Hwang RF, Ross MI, Kuerer HM, Luo S, Gonzalez-Angulo AM, Buzdar AU, Symmans WF, Feig BW, Lucci A, Huang EH, Hunt KK. Classification of ipsilateral breast tumor recurrences after breast conservation therapy can predict patient prognosis and facilitate treatment planning. Ann Surg 253(3):572-9, 3/2011. PMID: 21209588.
45. Gonzalez-Angulo AM, Timms KM, Liu S, Chen H, Litton JK, Potter J, Lanchbury JS, Stemke-Hale K, Hennessy BT, Arun BK, Hortobagyi GN, Do KA, Mills GB, Meric-Bernstam F. Incidence and outcome of BRCA mutations in unselected patients with triple receptor-negative breast cancer. Clin Cancer Res 17(5):1082-9, 3/2011. e-Pub 1/2011. PMCID: PMC3048924.
46. Kuerer HM, Buzdar AU, Mittendorf EA, Esteva FJ, Lucci A, Vence LM, Radvanyi L, Meric-Bernstam F, Hunt KK, Symmans WF. Biologic and immunologic effects of preoperative trastuzumab for ductal carcinoma in situ of the breast. Cancer 117(1):39-47, 1/1/2011. e-Pub 8/24/2010. PMCID: PMC2997136.
47. Singh G, Akcakanat A, Sharma C, Luyimbazi D, Naff KA, Meric-Bernstam F. The effect of leucine restriction on Akt/mTOR signaling in breast cancer cell lines in vitro and in vivo. Nutr Cancer 63(2):264-71, 2011. PMID: 21294052.
48. Valero V, Kong AL, Hunt KK, Yi M, Hwang RF, Meric-Bernstam F, Bedrosian I, Ross MI, Babiera GV, Litton JK, Mittendorf EA. Sentinel lymph node dissection is technically feasible in older breast cancer patients. Clin Breast Cancer 10(6):477-82, 12/1/2010. PMID: 21147692.
49. Hennessy BT, Lu Y, Gonzalez-Angulo AM, Carey MS, Myhre S, Ju Z, Davies MA, Liu W, Coombes K, Meric-Bernstam F, Bedrosian I, McGahren M, Agarwal R, Zhang F, Overgaard J, Alsner J, Neve RM, Kuo WL, Gray JW, Borresen-Dale AL, Mills GB. A Technical Assessment of the Utility of Reverse Phase Protein Arrays for the Study of the Functional Proteome in Non-microdissected Human Breast Cancers. Clin Proteomics 6(4):129-51, 12/2010. PMCID: PMC3116520.
50. Hall C, Krishnamurthy S, Lodhi A, Mosalpuria K, Kuerer HM, Meric-Bernstam F, Bedrosian I, Hunt KK, Lucci A. Disseminated Tumor Cells in Biologic Subtypes of Stage I-III Breast Cancer Patients. Ann Surg Oncol 17(12):3252-8, 12/2010. e-Pub 6/18/2010. PMID: 20559739.
51. Caudle AS, Gonzalez-Angulo AM, Hunt KK, Pusztai L, Kuerer HM, Mittendorf EA, Hortobagyi GN, Meric-Bernstam F. Impact of Progression During Neoadjuvant Chemotherapy on Surgical Management of Breast Cancer. Ann Surg Oncol. e-Pub 11/9/2010. PMID: 21061075.
52. McAuliffe PF, Meric-Bernstam F, Mills GB, Gonzalez-Angulo AM. Deciphering the Role of PI3K/Akt/mTOR Pathway in Breast Cancer Biology and Pathogenesis. Clin Breast Cancer 10:S59-65, 11/2010. PMID: 21115423.
53. Sharma R, Bedrosian I, Lucci A, Hwang RF, Rourke LL, Qiao W, Buchholz TA, Kronowitz SJ, Krishnamurthy S, Babiera GV, Gonzalez-Angulo AM, Meric-Bernstam F, Mittendorf EA, Hunt KK, Kuerer HM. Present-day locoregional control in patients with t1 or t2 breast cancer with 0 and 1 to 3 positive lymph nodes after mastectomy without radiotherapy. Ann Surg Oncol 17(11):2899-908, 11/2010. e-Pub 5/5/2010. PMID: 20443145.
54. Kang T, Yi M, Hunt KK, Mittendorf EA, Babiera GV, Kuerer H, Bedrosian I, Hwang RF, Lucci A, Meric-Bernstam F. Does blue dye contribute to success of sentinel node mapping for breast cancer? Ann Surg Oncol 17(Suppl 3):280-5, 10/2010. e-Pub 9/2010. PMID: 20853047.
55. Luyimbazi D, Akcakanat A, McAuliffe PF, Zhang L, Singh G, Gonzalez-Angulo AM, Chen H, Do KA, Zheng Y, Hung MC, Mills GB, Meric-Bernstam F. Rapamycin regulates Stearoyl CoA Desaturase 1 Expression in Breast Cancer. Mol Cancer Ther 9(10):2770-84, 10/2010. e-Pub 9/2010. PMCID: PMC2965451.
56. Yi M, Giordano SH, Meric-Bernstam F, Mittendorf EA, Kuerer HM, Hwang RF, Bedrosian I, Rourke L, Hunt KK. Trends in and outcomes from sentinel lymph node biopsy (SLNB) alone vs. SLNB with axillary lymph node dissection for node-positive breast cancer patients: experience from the SEER database. Ann Surg Oncol 17(Suppl 3):343-51, 10/2010. e-Pub 9/2010. PMID: 20853057.
57. Woodward WA, Truong PT, Yu TK, Tereffe W, Oh J, Perkins G, Strom E, Meric-Bernstam F, Gonzalez-Angulo AM, Speers C, Ragaz J, Buchholz TA. Among women who experience a recurrence after postmastectomy radiation therapy irradiation is not associated with more aggressive local recurrence or reduced survival. Breast Cancer Res Treat 123(2):597-605, 9/2010. e-Pub 3/20/2010. PMID: 20306128.
58. Yi M, Hunt KK, Arun BK, Bedrosian I, Barrera AG, Do KA, Kuerer HM, Babiera GV, Mittendorf EA, Ready K, Litton J, Meric-Bernstam F. Factors affecting the decision of breast cancer patients to undergo contralateral prophylactic mastectomy. Cancer Prev Res (Phila) 3(8):1026-34, 8/2010. e-Pub 7/2010. PMID: 20647335.
59. Dominici LS, Negron Gonzalez VM, Buzdar AU, Lucci A, Mittendorf EA, Le-Petross HT, Babiera GV, Meric-Bernstam F, Hunt KK, Kuerer HM. Cytologically proven axillary lymph node metastases are eradicated in patients receiving preoperative chemotherapy with concurrent trastuzumab for HER2-positive breast cancer. Cancer 116(12):2884-9, 6/15/2010. PMID: 20564395.
60. Brown AS, Hunt KK, Shen J, Huo L, Babiera GV, Ross MI, Meric-Bernstam F, Feig BW, Kuerer HM, Boughey JC, Ching CD, Gilcrease MZ. Histologic changes associated with false-negative sentinel lymph nodes after preoperative chemotherapy in patients with confirmed lymph node-positive breast cancer before treatment. Cancer 116(12):2878-83, 6/15/2010. PMID: 20564394.
61. Bedrosian I, Babiera GV, Mittendorf EA, Kuerer HM, Pantoja L, Hunt KK, Krishnamurthy S, Meric-Bernstam F. A Phase I Study to Assess the Feasibility and Oncologic Safety of Axillary Reverse Mapping in Breast Cancer Patients. Cancer 116(11):2543-8, 6/2010. PMID: 20336790.
62. Caudle AS, Gonzalez-Angulo AM, Hunt KK, Liu P, Pusztai L, Symmans WF, Kuerer HM, Mittendorf EA, Hortobagyi GN, Meric-Bernstam F. Predictors of Tumor Progression During Neoadjuvant Chemotherapy in Breast Cancer. J Clin Oncol 28(11):1821-8, 4/2010. e-Pub 3/2010. PMCID: PMC2860366.
63. Bose D, Meric-Bernstam F, Hofstetter W, Reardon DA, Flaherty KT, Ellis LM. Vascular endothelial growth factor targeted therapy in the perioperative setting: implications for patient care. Lancet Oncol 11(4):373-82, 4/2010. e-Pub 2/2010. PMID: 20171141.
64. Yang WT, Lewis MT, Hess K, Wong H, Tsimelzon A, Karadag N, Cairo M, Wei C, Meric-Bernstam F, Brown P, Arun B, Hortobagyi GN, Sahin A, Chang JC. Decreased TGFbeta signaling and increased COX2 expression in high risk women with increased mammographic breast density. Breast Cancer Res Treat 119(2):305-14, 1/2010. e-Pub 2/25/2009. PMID: 19241157.
65. Fearmonti RM, Gayed IW, Kim E, Bedrosian I, Hunt KK, Meric-Bernstam F, Feig B, Ghonimi E, Warneke C, Babiera GV. Intra-Individual Comparison of Lymphatic Drainage Patterns Using Subareolar and Peritumoral Isotope Injection for Breast Cancer. Ann Surg Oncol 17(1):220-7, 1/2010. e-Pub 8/13/2009. PMID: 19680729.
66. Rosbach KJ, Shin D, Muldoon TJ, Quraishi MA, Middleton LP, Hunt KK, Meric-Bernstam F, Yu TK, Richards-Kortum RR, Yang W. High-resolution fiber optic microscopy with fluorescent contrast enhancement for the identification of axillary lymph node metastases in breast cancer: a pilot study. Biomed Opt Express 1(3):911-922, 2010. e-Pub 9/16/2010. PMCID: PMC3018063.
67. Gonzalez-Angulo AM, Litton JK, Broglio KR, Meric-Bernstam F, Rakkhit R, Cardoso F, Peintinger F, Hanrahan EO, Sahin A, Guray M, Larsimont D, Feoli F, Stranzl H, Buchholz TA, Valero V, Theriault R, Piccart-Gebhart M, Ravdin PM, Berry DA, Hortobagyi GN. High risk of recurrence for patients with breast cancer who have human epidermal growth factor receptor 2-positive, node-negative tumors 1 cm or smaller. J Clin Oncol 27(34):5700-6, 12/2009. PMCID: PMC2792998.
68. Mittendorf EA, Wu Y, Scaltriti M, Meric-Bernstam F, Hunt KK, Dawood S, Esteva FJ, Buzdar AU, Chen H, Eksambi S, Hortobagyi GN, Baselga J, Gonzalez-Angulo AM. Loss of HER2 amplification following trastuzumab-based neoadjuvant systemic therapy and survival outcomes. Clin Cancer Res 15(23):7381-8, 12/2009. PMCID: PMC2788123.
69. Liedtke C, Broglio K, Moulder S, Hsu L, Kau SW, Symmans WF, Albarracin C, Meric-Bernstam F, Woodward W, Theriault RL, Kiesel L, Hortobagyi GN, Pusztai L, Gonzalez-Angulo AM. Prognostic impact of discordance between triple-receptor measurements in primary and recurrent breast cancer. Ann Oncol 20(12):1953-8, 12/2009. e-Pub 7/12/2009. PMCID: PMC2791352.
70. Fearmonti RM, Batista LI, Meric-Bernstam F, Bedrosian I, Kuerer HM, Hunt KK, Eva Singletary S, Babiera GV. False Negative Rate of Sentinel Lymph Node Biopsy in Multicentric and Multifocal Breast Cancers May be Higher in Cases with Large Additive Tumor Burden. Breast J 15(6):645-8, Nov-Dec, 11/2009. PMID: 19735388.
71. Boughey JC, Goravanchi F, Parris RN, Kee SS, Kowalski AM, Frenzel JC, Bedrosian I, Meric-Bernstam F, Hunt KK, Ames FC, Kuerer HM, Lucci A. Prospective randomized trial of paravertebral block for patients undergoing breast cancer surgery. Am J Surg 198(5):720-5, 11/2009. e-Pub 5/9/2009. PMID: 19427625.
72. Lucci A, Krishnamurthy S, Singh B, Bedrosian I, Meric-Bernstam F, Reuben J, Broglio K, Mosalpuria K, Lodhi A, Vincent L, Cristofanilli M. Cyclooxygenase-2 expression in primary breast cancers predicts dissemination of cancer cells to the bone marrow. Breast Cancer Res Treat 117(1):61-8, 9/2009. e-Pub 7/29/2008. PMID: 18663571.
73. Wagner J, Boughey JC, Garrett B, Babiera G, Kuerer H, Meric-Bernstam F, Singletary E, Hunt KK, Middleton LP, Bedrosian I. Margin assessment after neoadjuvant chemotherapy in invasive lobular cancer. Am J Surg 198(3):387-91, 9/2009. e-Pub 4/10/2009. PMID: 19362281.
74. Hunt KK, Yi M, Mittendorf EA, Guerrero C, Babiera GV, Bedrosian I, Hwang RF, Kuerer HM, Ross MI, Meric-Bernstam F. Sentinel Lymph Node Surgery After Neoadjuvant Chemotherapy is Accurate and Reduces the Need for Axillary Dissection in Breast Cancer Patients. Ann Surg. e-Pub 8/2009. PMID: 19730235.
75. Jiralerspong S, Palla SL, Giordano SH, Meric-Bernstam F, Liedtke C, Barnett CM, Hsu L, Hung MC, Hortobagyi GN, Gonzalez-Angulo AM. Metformin and pathologic complete responses to neoadjuvant chemotherapy in diabetic patients with breast cancer. J Clin Oncol 27(20):3297-302, 7/10/2009. e-Pub 6/1/2009. PMCID: PMC2736070.
76. Cabioglu N, Sahin AA, Morandi P, Meric-Bernstam F, Islam R, Lin HY, Bucana CD, Gonzalez-Angulo AM, Hortobagyi GN, Cristofanilli M. Chemokine receptors in advanced breast cancer: differential expression in metastatic disease sites with diagnostic and therapeutic implications. Ann Oncol 20(6):1013-9, 6/2009. e-Pub 2/23/2009. PMID: 19237480.
77. Boughey JC, Wagner J, Garrett BJ, Harker L, Middleton LP, Babiera GV, Meric-Bernstam F, Lucci A, Hunt KK, Bedrosian I. Neoadjuvant chemotherapy in invasive lobular carcinoma may not improve rates of breast conservation. Ann Surg Oncol 16(6):1606-11, 6/2009. e-Pub 3/12/2009. PMID: 19280264.
78. Zou CY, Smith KD, Zhu QS, Liu J, McCutcheon IE, Slopis JM, Meric-Bernstam F, Peng Z, Bornmann WG, Mills GB, Lazar AJ, Pollock RE, Lev D. Dual targeting of AKT and mammalian target of rapamycin: A potential therapeutic approach for malignant peripheral nerve sheath tumor. Mol Cancer Ther. e-Pub 5/5/2009. PMID: 19417153.
79. Meric-Bernstam F, Gonzalez-Angulo AM. Targeting the mTOR signaling network for cancer therapy. J Clin Oncol 27(13):2278-87, 5/1/2009. e-Pub 3/30/2009. PMCID: PMC2738634.
80. Krishnamurthy S, Meric-Bernstam F, Lucci A, Hwang RF, Kuerer HM, Babiera GV, Ames FC, Feig BW, Ross MI, Singletary SE, Hunt KK ,Bedrosian I. A prospective study comparing touch imprint cytology, frozen section analysis and rapid cytokeratin immunostain for intraoperative evaluation of axillary sentinel lymph nodes in breast cancer. Cancer 115(7):1361-2, 4/1/2009. e-Pub 2/2009. PMID: 19195040.
81. Litton JK, Westin SK, Ready K, Sun CC, Peterson S, Meric-Bernstam F, Gonzalez-Angulo AM, Bodurka DC, Lu K, Hortobagyi GN, Arun BK. Perception of screening and risk-reduction surgeries in patients tested for a BRCA deleterious mutation. Cancer 115(8):1598-604, 4/15/2009. PMCID: PMC2680417.
82. Yim EK, Peng G, Dai H, Hu R, Li K, Lu Y, Mills GB, Meric-Bernstam F, Hennessy BT, Craven RJ, Lin SY. Rak functions as a tumor suppressor by regulating PTEN protein stability and function. Cancer Cell 15(4):304-14, 4/7/2009. PMCID: PMC2673492.
83. Gonzalez-Angulo AM, Stemke-Hale K, Palla SL, Carey M, Agarwal R, Hsu L, Meric-Bernstam F, Traina TA, Hudis C, Hortobagyi GN, Gerald WL, Mills GB, Hennessy BT. Androgen receptor levels and association with PI3KCA mutations and prognosis in breast cancer. Clin Can Res 15(7):2472-8, 4/2009. PMID: 19276248.
84. Yim EK, Dai H, Li K, Mills GB, Meric-Bernstam F, Lin SY. Essential Role of Rak in PTEN Protein Stability and Tumor Suppression. Cancer Cell 15:304-314, 4/2009.
85. Beadle BM, Woodward WA, Tucker SL, Outlaw ED, Allen PK, Oh JL, Strom EA, Perkins GH, Tereffe W, Yu TK, Meric-Bernstam F, Litton JK, Buchholz TA. Ten-year recurrence rates in young women with breast cancer by locoregional treatment approach. Int J Radiat Oncol Biol Phys 73(3):734-44, 3/1/2009. e-Pub 8/15/2008. PMID: 18707822.
86. Beadle BM, Woodward WA, Middleton LP, Tereffe W, Strom EA, Litton JK, Meric-Bernstam F, Theriault RL, Buchholz TA, Perkins GH. The impact of pregnancy on breast cancer outcomes in women </=35 years. Cancer 115(6):1174-1184, 3/15/2009. e-Pub 2/2009. PMID: 19204903.
87. Yi M, Meric-Bernstam F, Middleton LP, Arun BK, Bedrosian I, Babiera GV, Hwang RF, Kuerer HM, Yang W, Hunt KK. Predictors of contralateral breast cancer in patients with unilateral breast cancer undergoing contralateral prophylactic mastectomy. Cancer 115(5):962-71, 3/2009. PMID: 19172584.
88. Lang JE, Mosalpuria K, Cristofanilli M, Krishnamurthy S, Reuben J, Singh B, Bedrosian I, Meric-Bernstam F, Lucci A. HER2 status predicts the presence of circulating tumor cells in patients with operable breast cancer. Breast Cancer Res Treat 113(3):501-7, 2/2009. e-Pub 3/9/2008. PMID: 18327638.
89. Arun B, Vogel K, Lopez A, Hernandez M, Atchley D, Broglio K, Amos CI, Meric-Bernstam F, Kuerer HM, Hortobagyi GN, Albarracin C. High Prevalence of Pre-invasive lesions adjacent to BRCA1/2-Associated Breast Cancers. Cancer Prev Res (Phila Pa) 2(2):122-7, 2/2009. e-Pub 1/27/2009. PMID: 19174581.
90. Kim D, Akcakanat A, Singh G, Sharma C, Meric-Bernstam F. Regulation and localization of ribosomal protein S6 kinase 1 isoforms. Growth Factors 27(1):12-21, 2/2009. NIHMSID: NIHMS169407.
91. Dawood S, Broglio K, Kau SW, Green MC, Giordano SH, Meric-Bernstam F, Buchholz TA, Albarracin CT, Yang WT, Hennessy BT, Hortobagyi GN, Gonzalez-Angulo AM. Triple Receptor-Negative Breast Cancer: The Effect of Race on Response to Primary Systemic Treatment and Survival Outcomes. J Clin Oncol 27(2):220-6, 1/10/2009. e-Pub 12/1/2008. PMID: 19047281.
92. Dong J, Akcakanat A, Stivers DN, Zhang J, Kim D, Meric-Bernstam F. RNA-Binding Specificity of Y-Box Protein 1. RNA Biol 6(1):59-64, Jan-Mar, 1/2009. e-Pub 1/2009. NIHMSID: NIHMS169405.
93. Akcakanat A, Zhang L, Tsavachidis S, Meric-Bernstam F. The rapamycin-regulated gene expression signature determines prognosis for breast cancer. Mol Cancer 8(1):75, 2009. PMCID: PMC2761377.
94. Yao JC, Phan AT, Chang DZ, Wolff RA, Hess K, Gupta S, Jacobs C,Mares JE, Landgraf AN, Rashid A, Meric-Bernstam F. Efficacy of RAD001 (Everolimus) and Octreotide LAR in Advanced Low- to Intermediate-Grade Neuroendocrine Tumors: Results of a Phase II Study. J Clin Oncol 26(26):4311-8, 9/2008. PMCID: PMCPMC2653122,.

Invited Articles

1. Chen AM, Meric-Bernstam F, Hunt KK, Buchholz TA. Neoadjuvant chemotherapy to permit breast conservation for patients with locally advanced breast cancer. Am J Oncol Rev 3:692-696, 2004.
2. Meric-Bernstam F, Bernstam EV. Breast Cancer on the World Wide Web. Breast Diseases: A Year Book Quarterly 14:20-23, 2003.
3. Meric-Bernstam F. Impact of positive surgical margins and ipsilateral breast tumor recurrence on disease-specific survival after breast-conserving therapy. Am J Oncol Rev 8:428-433, 2003.


1. Meric-Bernstam F. Heterogenic Loss of BRCA in Breast Cancer: The "Two-Hit" Hypothesis Takes a Hit. Ann Surg Oncol 14(9):2422-3, 9/2007. e-Pub 4/2007. PMID: 17406948.


1. Allen LR, Gadgil PV, Bassett R, Hunt KK, Mittendorf EA, Yi M, Babiera G, Kuerer HM, Ross MI, Bedrosian I, Meric-Bernstam F, Hwang RF. Nomogram to predict sentinel lymph node involvement in patients with clinically node-negative breast cancer receiving neoadjuvant chemotherapy. J Clin Oncol 30(suppl 27) (#150), 2012.

Letters to the Editor

1. Meric-Bernstam F (Invited Commentary). Patient selection for breast conservation after neoadjuvant chemotherapy: developing a prognostic index (Huang EH, et al). Am J Oncol Rev, 2006.

Last updated: 8/22/2015